The Myriad Genetics’ (MYGN) Hold Rating Reaffirmed at Jefferies Group LLC, Report finds

The Myriad Genetics’ (MYGN) Hold Rating Reaffirmed at Jefferies Group LLC, Report finds

Several other brokerages also recently weighed in on MYGN. Ladenburg Thalmann Financial Services upgraded Myriad Genetics from a sell rating to a neutral rating in a research note on Wednesday. TheStreet downgraded Myriad Genetics from a hold rating to a sell rating in a research note on Tuesday, November 1st. Zacks Investment Research upgraded Myriad Genetics from a sell rating to a hold rating in a research note on Wednesday, February 1st. Piper Jaffray Companies reiterated a neutral rating and set a $21.00 price target on shares of Myriad Genetics in a research note on Tuesday. Finally, Barclays PLC reiterated an equal weight rating and set a $22.00 price target on shares of Myriad Genetics in a research note on Tuesday, December 27th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $27.64.

Jefferies Group LLC reissued their hold rating on shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in a report issued on Wednesday morning. The brokerage currently has a $18.00 target price on the stock.

Shares of Myriad Genetics (NASDAQ:MYGN) traded down 2.30% on Wednesday, hitting $16.14. The stock had a trading volume of 1,990,762 shares. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $39.74. The company’s 50 day moving average price is $16.45 and its 200-day moving average price is $19.67. The company has a market cap of $1.10 billion, a P/E ratio of 18.24 and a beta of 0.26.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, February 7th. The company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.02. Myriad Genetics had a return on equity of 11.94% and a net margin of 8.08%. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $189.72 million. During the same period in the previous year, the business earned $0.45 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, analysts expect that Myriad Genetics will post $0.98 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its position in Myriad Genetics by 96.2% in the third quarter. Acrospire Investment Management LLC now owns 10,400 shares of the company’s stock worth $214,000 after buying an additional 5,100 shares during the last quarter. Zacks Investment Management purchased a new position in shares of Myriad Genetics during the third quarter worth approximately $273,000. Lombardia Capital Partners LLC purchased a new position in shares of Myriad Genetics during the third quarter worth approximately $319,000. Royal Bank of Canada boosted its position in shares of Myriad Genetics by 21.6% in the second quarter. Royal Bank of Canada now owns 10,431 shares of the company’s stock worth $321,000 after buying an additional 1,851 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in shares of Myriad Genetics by 1.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 21,376 shares of the company’s stock worth $356,000 after buying an additional 301 shares during the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Related posts

Leave a Comment